K
Karl S. Peggs
Researcher at University College London
Publications - 269
Citations - 24298
Karl S. Peggs is an academic researcher from University College London. The author has contributed to research in topics: Transplantation & T cell. The author has an hindex of 66, co-authored 250 publications receiving 20382 citations. Previous affiliations of Karl S. Peggs include National Health Service & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan,Nicholas McGranahan,Andrew Furness,Rachel Rosenthal,Sofie Ramskov,Rikke Birgitte Lyngaa,Sunil Kumar Saini,Mariam Jamal-Hanjani,Gareth A. Wilson,Nicolai Juul Birkbak,Crispin T. Hiley,Thomas B.K. Watkins,Seema Shafi,Nirupa Murugaesu,Richard Mitter,Ayse U. Akarca,Joseph Linares,Teresa Marafioti,Jake Y. Henry,Eliezer M. Van Allen,Eliezer M. Van Allen,Diana Miao,Diana Miao,Bastian Schilling,Dirk Schadendorf,Levi A. Garraway,Levi A. Garraway,Vladimir Makarov,Naiyer A. Rizvi,Alexandra Snyder,Alexandra Snyder,Matthew D. Hellmann,Matthew D. Hellmann,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Sachet A. Shukla,Sachet A. Shukla,Catherine J. Wu,Karl S. Peggs,Timothy A. Chan,Sine Reker Hadrup,Sergio A. Quezada,Charles Swanton +43 more
TL;DR: A relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas and the impact of neoantigens intratumor heterogeneity (ITH) on antitumor immunity is demonstrated.
Journal ArticleDOI
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,Jae H. Park,Elena Mead,Steven Z. Pavletic,William Y. Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Marcel R.M. van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
Journal ArticleDOI
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R. Simpson,Fubin Li,Welby Montalvo-Ortiz,Manuel A. Sepulveda,Katharina Bergerhoff,Frederick Arce,Claire Roddie,Jake Y. Henry,Hideo Yagita,Jedd D. Wolchok,Karl S. Peggs,Jeffrey V. Ravetch,James P. Allison,Sergio A. Quezada +13 more
TL;DR: Anti–CTLA-4 antibody induces selective depletion of T reg cells within tumor lesions in a manner that is dependent on the presence of Fc gamma receptor-expressing macrophages within the tumor microenvironment.
Journal ArticleDOI
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh,Nicolai Juul Birkbak,Nicolai Juul Birkbak,Gareth A. Wilson,Gareth A. Wilson,Mariam Jamal-Hanjani,Tudor Constantin,Raheleh Salari,John Le Quesne,David A. Moore,Selvaraju Veeriah,Rachel Rosenthal,Teresa Marafioti,Eser Kirkizlar,Thomas B.K. Watkins,Thomas B.K. Watkins,Nicholas McGranahan,Nicholas McGranahan,Sophia Ward,Sophia Ward,Luke Martinson,Joan Riley,Francesco Fraioli,Maise Al Bakir,Eva Grönroos,Francisco Zambrana,Raymondo Endozo,Wenya Linda Bi,Wenya Linda Bi,Fiona M. Fennessy,Fiona M. Fennessy,Nicole Sponer,Diana Johnson,Joanne Laycock,Seema Shafi,Justyna Czyzewska-Khan,Andrew Rowan,Tim Chambers,Nik Matthews,Nik Matthews,Samra Turajlic,Samra Turajlic,Crispin T. Hiley,Crispin T. Hiley,Siow Ming Lee,Martin Forster,Tanya Ahmad,Mary Falzon,Elaine Borg,David Lawrence,Martin Hayward,Shyam Kolvekar,Nikolaos Panagiotopoulos,Sam M. Janes,Ricky Thakrar,Asia Ahmed,Fiona H Blackhall,Yvonne Summers,Dina Hafez,Ashwini Naik,Apratim Ganguly,Stephanie Kareht,Rajesh Shah,Leena Dennis Joseph,Anne Marie Quinn,Phil Crosbie,Babu Naidu,Gary Middleton,Gerald Langman,Simon Trotter,Marianne Nicolson,Hardy Remmen,Keith M. Kerr,Mahendran Chetty,Lesley Gomersall,Dean A. Fennell,Apostolos Nakas,Sridhar Rathinam,Girija Anand,Sajid Khan,Peter Russell,Veni Ezhil,Babikir Ismail,Melanie Irvin-Sellers,Vineet Prakash,Jason F. Lester,Malgorzata Kornaszewska,Richard Attanoos,Haydn Adams,Helen E. Davies,Dahmane Oukrif,Ayse U. Akarca,John A. Hartley,Helen Lowe,Sara Lock,Natasha Iles,Harriet Bell,Yenting Ngai,Greg Elgar,Zoltan Szallasi,Zoltan Szallasi,Zoltan Szallasi,Roland F. Schwarz,Javier Herrero,Aengus Stewart,Sergio A. Quezada,Karl S. Peggs,Peter Van Loo,Peter Van Loo,Caroline Dive,Caroline Dive,C. Jimmy Lin,Matthew Rabinowitz,Hugo J.W.L. Aerts,Hugo J.W.L. Aerts,Allan Hackshaw,Jacqui Shaw,Bernhard Zimmermann,Charles Swanton,Charles Swanton +119 more
TL;DR: It is shown that phylogenetic ct DNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
Journal ArticleDOI
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
TL;DR: It is concluded that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–CTLA- 4 antibodies during cancer immunotherapy.